Detalles de la búsqueda
1.
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor.
Nat Med;
28(10): 2171-2182, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36216931
2.
Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer.
J Med Chem;
63(13): 6679-6693, 2020 07 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32250617
3.
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity.
ACS Med Chem Lett;
9(12): 1230-1234, 2018 Dec 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-30613331
4.
A Next-Generation TRK Kinase Inhibitor Overcomes Acquired Resistance to Prior TRK Kinase Inhibition in Patients with TRK Fusion-Positive Solid Tumors.
Cancer Discov;
7(9): 963-972, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28578312
5.
Selective inhibition of tropomyosin-receptor-kinase A (TrkA) reduces pain and joint damage in two rat models of inflammatory arthritis.
Arthritis Res Ther;
18(1): 97, 2016 05 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-27145816
6.
Sustained blockade of neurotrophin receptors TrkA, TrkB and TrkC reduces non-malignant skeletal pain but not the maintenance of sensory and sympathetic nerve fibers.
Bone;
48(2): 389-98, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-20854944
Resultados
1 -
6
de 6
1
Próxima >
>>